Multiple endocrine neoplasia type 2 historical perspective

Jump to navigation Jump to search

Multiple endocrine neoplasia type 2 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 2 from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Criteria

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Multiple endocrine neoplasia type 2 historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 2 historical perspective

CDC on Multiple endocrine neoplasia type 2 historical perspective

Multiple endocrine neoplasia type 2 historical perspective in the news

Blogs on Multiple endocrine neoplasia type 2 historical perspective

Directions to Hospitals Treating Multiple endocrine neoplasia type 2

Risk calculators and risk factors for Multiple endocrine neoplasia type 2 historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2] , Ammu Susheela, M.D. [3]

Overview

Multiple endocrine neoplasia type 2 was first described by Dr. John H. Sipple, an American physician, in 1961 by reporting a case of a patient with pheochromocytoma, medullary thyroid carcinoma, and parathyroid adenoma.

Historical Perspective

The historical background of multiple endocrine neoplasia type 2 is given in the table below:[1][2][3][4][5]


MEN II Historical Background
Years Scientist Contribution
1954 Wermer Reported that syndrome was transmitted as a dominant trait
1959 Hazard Described medullary (solid) thyroid carcinoma
1961 Sipple Described a case of a patient with pheochromocytoma, medullary thyroid carcinoma, and parathyroid adenoma. It was based on a case he saw when he was in 3rd year medical residency about a person with intracranial bleed and fluctuating blood pressure. His autopsy showed parathyroid tumor, thyroid tumor, and bilateral adrenal pheochromocytomas.
1965 Schimke and Hartmann Described a syndrome of medullary thyroid carcinoma with abundant amyloid stroma and pheochromocytoma
1966 Williams Reported a case of a patient with combination of mucosal neuromas, pheochromocytoma, and medullary thyroid carcinoma
1968 Steiner Introduced the term "multiple endocrine neoplasia" (MEN) to describe disorders featuring combinations of endocrine tumors and proposed the terms 'Wermer syndrome' for multiple endocrine neoplasia type 1 and 'Sipple syndrome' for multiple endocrine neoplasia type 2
Meyer and Abdel-Bari Suggested that medullary carcinoma produces thyrocalcitonin from parafollicular cells
1970 Kaplan Suggested that adrenal medulla produces a calcitonin like material
1974 Sizemore Showed that the multiple endocrine neoplasia type 2 category included two groups of patients with medullary thyroid cancer and pheochromocytoma: one with parathyroid disease and a normal appearance (multiple endocrine neoplasia type 2A) and the other without parathyroid disease but with mucosal neuromas and mesodermal abnormalities (multiple endocrine neoplasia type 2B)
1978 Hamilton Reported a case of Zollinger-Ellison syndrome in multiple endocrine hyperplasia type 2
Cameron Suggested that medullary carcinoma produces thyrocalcitonin from parafollicular cells
1980 Le Marec Described a case of congential megacolon in Sipple syndrome
1989 Sobol Proposed that restriction fragment length polymerase is useful in predicting the carrier state of multiple endocrine neoplasia syndrome
1993 RET germline mutations were recognized as the causative molecular alterations in multiple endocrine neoplasia type 2 syndromes
1998 MEN1 gene was cloned

2000-2001

Huang,Koch

Introduced the 2 hit mechanism for multiple endocrine neoplasia type 2 associated tumors and also described the mechanism of involved in trisomy 10

References

  1. Schimke RN, Hartmann WH (1965). "Familial amyloid-producing medullary thyroid carcinoma and pheochromocytoma. A distinct genetic entity". Ann Intern Med. 63 (6): 1027–39. PMID 5844561.
  2. Kaplan EL, Arnaud CD, Hill BJ, Peskin GW (1970). "Adrenal medullary calcitonin-like factor: a key to multiple endocrine neoplasia, type 2?". Surgery. 68 (1): 146–9. PMID 10483461.
  3. Cameron D, Spiro HM, Landsberg L (1978). "Zollinger-Ellison syndrome with multiple endocrine adenomatosis type II". N Engl J Med. 299 (3): 152–3. doi:10.1056/NEJM197807202990315. PMID 26873.
  4. Le Marec B, Roussey M, Cornec A, Calmettes C, Kerisit J, Allanic H (1981). "[Thyroid cancer with amyloid stroma, Sipple's syndrome, congenital megacolon with plexus hyperplasia: one and the same dominant autosomal disease with complete penetrance]". J Genet Hum. 28 (5): 169–74. PMID 7276917.
  5. Guru SC, Manickam P, Crabtree JS, Olufemi SE, Agarwal SK, Debelenko LV. Identification and characterization of the multiple endocrine neoplasia type 1 (MEN1) gene. J Intern Med 243(6) 433-9


Template:WikiDoc Sources